The Ministry of Defense released the following statement:
The Israel Institute for Biological Research (IIBR) and international pharma company, NRx Pharmaceuticals, announce that following the MOU signed between the parties, a delivery of 1,125 vaccine vials was sent over the weekend and landed in Georgia in order to expand the second phase of clinical trials for the BriLife corona vaccine developed by the IIBR.
The clinical trials in Georgia will take place simultaneously to the recruitment of volunteers and completion of the second phase of clinical trials in Israel. NRx pharmaceuticals is expanding the second phase of clinical trials abroad in order to increase the statistical sample and prepare the regulatory file necessary in order to approve further trials. IIBR will accompany the process and will continue to provide scientific knowledge in order to complete the trials.
The All Israel News Staff is a team of journalists in Israel.